Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
The biotech is floating a relatively sizable secondary share issue.
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
Overview
MoonLake Immunotherapeutics (NASDAQ: MLTX) clearly wasn't immune to negative investor sentiment on Wednesday. The clinical-stage biotech's equity slumped by almost 6% during that trading session, mainly due to a secondary share issue announced by the company.
Late Tuesday night, MoonLake announced the pricing of the share issue, adding that it had been upsized.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
